secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001213900-24-076108
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LYMPHIR added to NCCN Guidelines for CTCL treatment
---------------------------------------------------

- NCCN Category 2A recommendation supports LYMPHIR as option for relapsed/refractory CTCL after at least one prior systemic therapy.
- LYMPHIR targets IL-2 receptor on malignant T-cells; FDA approved based on Phase 3 study results.
- CEO says NCCN inclusion could aid physician adoption and ease reimbursement, potentially expanding CMS coverage.
- Citius Pharma (CTXR) and Citius Oncology (CTOR) jointly announced the guideline addition on Sep 5, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024076108/0001213900-24-076108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024076108/ea0213639-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-076108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer